50/120
2.1 / 5 stars
All 120 Win/Lose results shown below
MRK Roast Me summary
Merck & Co., Inc. (MRK). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseMRK / S&P 7.59% / 15.20% |
LoseMRK / S&P 4.64% / 15.00% |
LoseMRK / S&P -80.59% / 50.40% |
| 2026-Q11/3 |
WinMRK / S&P 15.13% / -4.33% |
LoseMRK / S&P 2.89% / 11.30% |
LoseMRK / S&P -48.18% / 27.70% |
| 2025-Q41/3 |
WinMRK / S&P 26.49% / 2.65% |
LoseMRK / S&P 1.31% / 9.00% |
LoseMRK / S&P 8.01% / 13.40% |
| 2025-Q31/3 |
LoseMRK / S&P 7.07% / 8.12% |
LoseMRK / S&P 1.68% / 4.61% |
WinMRK / S&P 58.70% / 13.45% |
| 2025-Q21/3 |
LoseMRK / S&P -10.93% / 10.94% |
LoseMRK / S&P 1.82% / 4.83% |
WinMRK / S&P 20.41% / 10.63% |
| 2025-Q11/3 |
LoseMRK / S&P -8.99% / -4.27% |
LoseMRK / S&P 4.10% / 4.98% |
WinMRK / S&P 663.33% / 10.57% |
| 2024-Q42/3 |
LoseMRK / S&P -11.70% / 2.41% |
WinMRK / S&P 6.74% / 5.25% |
WinMRK / S&P 4714.29% / 6.15% |
| 2024-Q32/3 |
LoseMRK / S&P -7.66% / 5.89% |
WinMRK / S&P 6.51% / 5.89% |
WinMRK / S&P 165.00% / 6.11% |
| 2024-Q22/3 |
LoseMRK / S&P -5.62% / 4.28% |
WinMRK / S&P 7.15% / 5.38% |
WinMRK / S&P 341.80% / 5.12% |
| 2024-Q12/3 |
WinMRK / S&P 21.80% / 10.56% |
WinMRK / S&P 6.11% / 5.71% |
LoseMRK / S&P -82.42% / 5.59% |
| 2023-Q40/3 |
LoseMRK / S&P 6.66% / 11.69% |
LoseMRK / S&P 1.40% / 6.81% |
LoseMRK / S&P -97.55% / 7.78% |
| 2023-Q30/3 |
LoseMRK / S&P -10.17% / -3.27% |
LoseMRK / S&P 0.58% / 7.52% |
LoseMRK / S&P -70.05% / -5.03% |
| 2023-Q21/3 |
WinMRK / S&P 9.18% / 8.74% |
LoseMRK / S&P 2.00% / 9.50% |
LoseMRK / S&P -81.32% / -8.57% |
| 2023-Q11/3 |
LoseMRK / S&P -3.44% / 7.50% |
LoseMRK / S&P 7.21% / 10.77% |
WinMRK / S&P -8.41% / -15.69% |
| 2022-Q43/3 |
WinMRK / S&P 29.69% / 7.56% |
WinMRK / S&P 21.72% / 11.88% |
WinMRK / S&P 11.09% / -17.99% |
| 2022-Q33/3 |
WinMRK / S&P -4.78% / -4.88% |
WinMRK / S&P 27.84% / 13.47% |
WinMRK / S&P 112.37% / -1.41% |
| 2022-Q23/3 |
WinMRK / S&P 12.02% / -16.10% |
WinMRK / S&P 30.21% / 13.71% |
WinMRK / S&P 198.17% / 11.04% |
| 2022-Q13/3 |
WinMRK / S&P 8.01% / -4.60% |
WinMRK / S&P 28.96% / 15.97% |
WinMRK / S&P 102.54% / 42.23% |
| 2021-Q41/3 |
LoseMRK / S&P 3.01% / 11.03% |
WinMRK / S&P 17.31% / 15.00% |
LoseMRK / S&P 84.89% / 96.40% |
| 2021-Q31/3 |
LoseMRK / S&P -2.55% / 0.58% |
WinMRK / S&P 26.43% / 10.77% |
LoseMRK / S&P -37.39% / 69.42% |
| 2021-Q21/3 |
LoseMRK / S&P 6.63% / 8.55% |
WinMRK / S&P 15.68% / 6.58% |
LoseMRK / S&P -46.59% / 51.81% |
| 2021-Q11/3 |
LoseMRK / S&P -4.93% / 6.17% |
WinMRK / S&P 3.70% / -1.06% |
LoseMRK / S&P -30.13% / 7.39% |
| 2020-Q42/3 |
LoseMRK / S&P -0.61% / 12.15% |
WinMRK / S&P 6.13% / -3.72% |
WinMRK / S&P -27.03% / -33.42% |
| 2020-Q31/3 |
LoseMRK / S&P 8.05% / 8.93% |
LoseMRK / S&P -20.63% / -2.04% |
WinMRK / S&P 26.26% / -27.10% |
| 2020-Q21/3 |
LoseMRK / S&P 1.31% / 20.54% |
LoseMRK / S&P -14.45% / -0.46% |
WinMRK / S&P 14.85% / -27.11% |
| 2020-Q12/3 |
WinMRK / S&P -14.71% / -19.60% |
LoseMRK / S&P -6.29% / 3.47% |
WinMRK / S&P 24.61% / -14.75% |
| 2019-Q41/3 |
LoseMRK / S&P 8.78% / 9.07% |
LoseMRK / S&P -7.50% / 5.36% |
WinMRK / S&P 64.22% / 2.99% |
| 2019-Q32/3 |
LoseMRK / S&P 1.06% / 1.70% |
WinMRK / S&P 10.17% / 5.02% |
WinMRK / S&P 186.40% / 0.21% |
| 2019-Q22/3 |
LoseMRK / S&P 1.49% / 4.30% |
WinMRK / S&P 7.53% / 6.64% |
WinMRK / S&P 614.00% / 8.65% |
| 2019-Q11/3 |
LoseMRK / S&P 9.59% / 13.65% |
LoseMRK / S&P 5.77% / 8.12% |
WinMRK / S&P 446.55% / 14.29% |
| 2018-Q42/3 |
WinMRK / S&P 8.47% / -13.52% |
LoseMRK / S&P 5.41% / 9.05% |
WinMRK / S&P 166.67% / 18.23% |
| 2018-Q32/3 |
WinMRK / S&P 17.67% / 7.71% |
LoseMRK / S&P MRK unavailable / 10.21% |
WinMRK / S&P 20.19% / 19.06% |
| 2018-Q21/3 |
WinMRK / S&P 12.30% / 3.43% |
LoseMRK / S&P MRK unavailable / 9.03% |
LoseMRK / S&P -72.83% / 14.46% |
| 2018-Q10/3 |
LoseMRK / S&P -2.35% / -0.76% |
LoseMRK / S&P MRK unavailable / 7.68% |
LoseMRK / S&P -62.82% / 12.46% |
| 2017-Q40/3 |
LoseMRK / S&P -11.37% / 6.64% |
LoseMRK / S&P 0.79% / 7.03% |
LoseMRK / S&P -38.30% / 13.82% |
| 2017-Q30/3 |
LoseMRK / S&P 0.63% / 4.48% |
LoseMRK / S&P MRK unavailable / 5.68% |
LoseMRK / S&P -46.67% / 17.57% |
| 2017-Q20/3 |
LoseMRK / S&P 1.61% / 3.09% |
LoseMRK / S&P MRK unavailable / 4.83% |
LoseMRK / S&P 1.66% / 17.74% |
| 2017-Q11/3 |
WinMRK / S&P 8.71% / 6.07% |
LoseMRK / S&P MRK unavailable / 3.67% |
LoseMRK / S&P -3.70% / 13.32% |
| 2016-Q40/3 |
LoseMRK / S&P -4.95% / 3.82% |
LoseMRK / S&P MRK unavailable / 2.09% |
LoseMRK / S&P -9.62% / 7.05% |
| 2016-Q31/3 |
WinMRK / S&P 9.13% / 3.85% |
LoseMRK / S&P MRK unavailable / 0.20% |
LoseMRK / S&P -47.44% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | MRK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 82.20% | 20.78% |
| Annualized return | 82.20% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | MRK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 127.54% | 83.14% |
| Annualized return | 17.87% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | MRK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 235.81% | 319.30% |
| Annualized return | 12.88% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |